Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.85 |
| ▸ | DRD3 | P35462 | 7/20 | 0.85 |
| ▸ | DRD4 | P21917 | 6/20 | 0.85 |
| ▸ | HTR1A | P08908 | 4/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14761584 | 0.93 | DRD2 (0.94) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL14761722 | 0.92 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL10911336 | 0.92 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL14761605 | 0.91 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL9652182 | 0.87 | DRD2 (0.72) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL17194866 | 0.86 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL10910646 | 0.85 | DRD2 (0.94) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL10911858 | 0.85 | DRD2 (0.85) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL8498530 | 0.85 | DRD2 (0.64) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL9652784 | 0.84 | DRD2 (0.72) | DRD2DRD4HTR1AADRA1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59055878-A | — | — | None | — | — | JP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-6344458-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-05 | — | — | US | disclosed |
| EP-0104614-B1 | PHENYLPIPERAZINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4560686-A | Method for treating circulatory diseases by using (2-lower alkoxyphenyl)piperazine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| EP-0104614-A1 | Phenylpiperazine derivatives and process for producing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1984-04-04 | — | — | EP | disclosed |
| JP-S5955878-A | NOVEL PHENYLPIPERAZINE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1984-03-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | DRD2 63/4885DRD3 102/4885DRD4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.